1149 related articles for article (PubMed ID: 17506785)
1. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
5. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
6. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
7. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.
Trocóniz IF; Tillmann C; Liesenfeld KH; Schäfer HG; Stangier J
J Clin Pharmacol; 2007 Mar; 47(3):371-82. PubMed ID: 17322149
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran etexilate in venous thromboembolism.
Ferrer E
Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
[TBL] [Abstract][Full Text] [Related]
17. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
18. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
20. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
Blech S; Ebner T; Ludwig-Schwellinger E; Stangier J; Roth W
Drug Metab Dispos; 2008 Feb; 36(2):386-99. PubMed ID: 18006647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]